Quarterly report [Sections 13 or 15(d)]

License Agreements (Details)

v3.25.1
License Agreements (Details) - USD ($)
 1 Months Ended
Mar. 31, 2015
Jan. 31, 2019
May 31, 2016
NeuPharma, Inc. | Additional sales milestone      
License Agreements      
Maximum potential milestone payments $ 40,000,000    
NeuPharma, Inc. | Clinical and development milestone      
License Agreements      
Maximum potential milestone payments 39,000,000    
NeuPharma, Inc. | Regulatory approvals to commercialize the products      
License Agreements      
Maximum potential milestone payments 22,500,000    
Dana-Farber Cancer Institute      
License Agreements      
Amount of milestone expensed 5,000,000    
Maintenance fee 50,000    
Dana-Farber Cancer Institute | First commercial sale milestone      
License Agreements      
Maximum potential milestone payments 21,500,000    
Dana-Farber Cancer Institute | Additional sales milestone      
License Agreements      
Maximum potential milestone payments $ 60,000,000    
Adimab, LLC | Regulatory approvals to commercialize the products      
License Agreements      
Maximum potential milestone payments   $ 2,500,000  
Jubilant Biosys Limited | Clinical and development milestone      
License Agreements      
Maximum potential milestone payments     $ 88,400,000
Jubilant Biosys Limited | Regulatory approvals to commercialize the products      
License Agreements      
Maximum potential milestone payments     59,500,000
Jubilant Biosys Limited | Sales milestone      
License Agreements      
Maximum potential milestone payments     $ 89,300,000